Seroprevalences of antibodies against pertussis,diphtheria, tetanus,measles, mumps and rubella: A cross-sectional study in children following vaccination procedure in Guangzhou,China |
| |
| Affiliation: | 1. Department of Pediatrics, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, PR China;2. Pediatric Intensive Care Unit, Beijing Children''s Hospital, Capital Medical University, National Center for Children''s Health, Beijing, PR China;3. Department of Pediatrics, the First People’s Hospital of Foshan, Foshan, PR China;4. Department of Clinical Laboratory, Nanhai Hospital Affiliated to Southern Medical University, Foshan, PR China;1. Emergency Department, General Hospital of Chinese PLA, Beijing 100853, China;2. Medical Support Department, General Hospital of Chinese PLA, Beijing 100853, China;3. Cardiology Department of Chinese PLA, Beijing 100853, China;1. Institut de la Francophonie pour la Medecine Tropicale, Lao Democratic People’s Republic;2. Lao-Lux Laboratory, Institut Pasteur du Laos, Vientiane, Lao Democratic People’s Republic;4. Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg;5. Laboratoire Nationale de Santé, Dudelange, Luxembourg;1. Research and Development, CSL Behring GmbH, Marburg, Germany;2. Research and Development, CSL Limited, BIO21 Institute, Parkville, VIC, Australia;3. CSL Behring, Danderyd, Sweden;4. Research and Development, CSL Behring Lengnau AG, Lengnau, Switzerland;1. Assistant Professor, Department of Microbiology, Armed Forces Medical College, Pune 411040, India;2. Professor & Head, Department of Microbiology, Armed Forces Medical College, Pune 411040, India;3. PMO, HQ Central Air Command, Allahabad, India;4. Principal, College of Nursing, Armed Forces Medical College, Pune 411040, India;5. Dean and Deputy Commandant, Armed Forces Medical College, Pune 411040, India;1. Global Immunization Division, US Centers for Disease Control and Prevention, Atlanta, United States;2. Solomon Islands Ministry of Health and Medical Services, Honiara, Solomon Islands;3. Division of Parasitic Diseases and Malaria, US Centers for Disease Control and Prevention, Atlanta, United States;4. World Health Organization Office of the Western Pacific Region, Manila, Philippines |
| |
| Abstract: | This study investigated the concentrations and seroprevalence of immunoglobulin G (IgG) antibodies against pertussis, diphtheria, tetanus, measles, mumps and rubella among children in Guangzhou, China. We conducted a cross-sectional study focusing on the post-vaccination immune statuses of children on scheduled immunisation. Human IgG antibody against six diseases were measured using commercial enzyme-linked immunosorbent assay kits. Of 620 subjects, the male-to-female ratio was 2.04 (416/204). Seroprevalence (81.97% vs 90.20%) and IgG concentrations (686.55 IU/mL vs 884.26 IU/mL, P < 0.05) for measles, tetanus (0.94 IU/mL vs 1.21 IU/mL) and rubella (34.33 IU/mL vs 47.37 IU/mL) were all higher in females. No differences based on sex were observed in the seroprevalence and IgG concentrations for anti-pertussis antibodies, anti-diphtheria antibodies and anti-mumps. Slight increase in seroprevalence and IgG concentration occurred with anti-pertussis antibodies after primary and booster vaccinations (from 0.00% [1 m], 5.45% [6 m], to 17.14% [1.5 yr]; and from 8.57% [5 yr] to 15.79% [6 yr]). Although no booster vaccination was given after age 6 yr, the seroprevalence and IgG concentration for anti-pertussis antibodies remained relatively stable. For diphtheria, tetanus, measles and rubella, seroprevalence reached their peaks after the primary and first booster vaccination. A plateau occurred after age 1.5 yr with a declining trend in subjects >8–10 yr. The IgG concentrations of these 4 pathogens showed a dramatic increase after primary vaccination, with steadily declining trends thereafter. For mumps, subjects showed increased seroprevalence and IgG concentration after the primary mumps-containing vaccination in 1.5-yr-olds (from 7.14% to 57.14%; 52.13 IU/mL to 214.18 IU/mL); however, following that low seroprevalence levels (from 42.86% to 80.00%) were observed. The post-vaccination immune statuses against diphtheria, tetanus, measles and rubella were relatively satisfactory, compared to those against pertussis and mumps. Booster vaccination against pertussis and mumps at appropriate time should be considered. |
| |
| Keywords: | Seroprevalence Immunisation Diphtheria Tetanus Measles Rubella ELISA" },{" #name" :" keyword" ," $" :{" id" :" k0040" }," $$" :[{" #name" :" text" ," _" :" enzyme-linked immunosorbent assay IgG" },{" #name" :" keyword" ," $" :{" id" :" k0050" }," $$" :[{" #name" :" text" ," _" :" immunoglobulin G DT" },{" #name" :" keyword" ," $" :{" id" :" k0060" }," $$" :[{" #name" :" text" ," _" :" diphtheria toxoid DTaP" },{" #name" :" keyword" ," $" :{" id" :" k0070" }," $$" :[{" #name" :" text" ," _" :" combined diphtheria, tetanus, acellular pertussis vaccine DTwP" },{" #name" :" keyword" ," $" :{" id" :" k0080" }," $$" :[{" #name" :" text" ," _" :" combined diphtheria, tetanus, whole-cell pertussis vaccine MMR" },{" #name" :" keyword" ," $" :{" id" :" k0090" }," $$" :[{" #name" :" text" ," _" :" Measles, Mumps, and Rubella MR" },{" #name" :" keyword" ," $" :{" id" :" k0100" }," $$" :[{" #name" :" text" ," _" :" Measles and Rubella NIP" },{" #name" :" keyword" ," $" :{" id" :" k0110" }," $$" :[{" #name" :" text" ," _" :" national childhood immunisation program PT" },{" #name" :" keyword" ," $" :{" id" :" k0120" }," $$" :[{" #name" :" text" ," _" :" pertussis toxoid TT" },{" #name" :" keyword" ," $" :{" id" :" k0130" }," $$" :[{" #name" :" text" ," _" :" tetanus toxoid |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
